中重度特应性皮炎患者使用度普利尤单抗是否需要常规安全检测
该研究基于三项III期试验(LIBERTY AD SOLO 1、SOLO 2、CHRONOS),分析中重度特应性皮炎患者接受度普利尤单抗或安慰剂治疗期间血细胞、血生化和尿生化指标的变化。结果显示,未发现与度普利尤单抗相关的具有临床意义的实验室指标变化,结论认为使用度普利尤单抗治疗中重度特应性皮炎无需常规实验室检测。
要点
- 度普利尤单抗治疗中重度特应性皮炎未引起具临床意义的实验室指标变化。
- 基于三项III期试验数据,中重度特应性皮炎患者使用度普利尤单抗无需常规实验室检测。
- 该结论来自德国和美国作者对血细胞、血生化及尿生化指标的分析。
核心结论
- 中重度特应性皮炎患者使用度普利尤单抗无需常规实验室检测。
研究设计与样本
- 分析三项III期安慰剂对照试验(LIBERTY AD SOLO 1、SOLO 2、CHRONOS)中超过2000例患者长达一年的血尿实验室检测数据。
主要发现
- 对患者血细胞、血生化和尿生化进行多项常规实验室检测后,未发现与度普利尤单抗相关的具有临床意义的变化。
临床怎么用
- 中重度特应性皮炎患者使用度普利尤单抗时,无需进行常规实验室安全检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atopic dermatitis (also known as AD or eczema) is a common skin disease that can cause intense and persistent itching and rashes. Skin creams or ointments are not suitable or effective for some patients with moderate-to-severe AD. In these patients, oral (taken by mouth) or injected medications may be required. Some of those oral or injected treatments could be toxic and often have unwanted side effects, especially when used for a longer period of time, so patients must be regularly tested to see whether those treatments are harming their blood or organs. Dupilumab is a newer injectable drug for treating moderate-to-severe AD. Dupilumab specifically targets key molecules in the body that cause AD. Dupilumab has been tested for up to one year in more than 2000 patients enroled in placebo-controlled clinical trials. During those trials, patients provided blood and urine samples for laboratory testing while they were being treated with dupilumab or placebo (dummy drug). In this paper, the authors from Germany and the U.S.A, analysed how blood cells, blood chemistry, and urine chemistry changed during treatment, to check whether dupilumab is safe to use without the need for regular laboratory tests. After performing many routine laboratory tests on patients' blood and urine, they found that there were no clinically important changes in test results that could be linked to dupilumab. They concluded that patients using dupilumab for moderate-to-severe AD do not need routine laboratory testing. This is a summary of the study: Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
引用
- Wollenberg A, Beck LA, Blauvelt A, et al. Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis. Br J Dermatol. 2020. PMID: 32476149. doi:10.1111/bjd.19065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。